Navigation Links
Long-term Use of Antiepileptic Drug Vimpat® (Lacosamide) C-V Reduced Seizure Frequency and Severity and Improved Health-related Quality of Life Measures
Date:12/5/2011

d improvement in their overall health state, with nearly half (46.9 percent) placed in the "very much" or "much improved" categories.

About Epilepsy
Epilepsy is a chronic neurological disorder affecting approximately 50 million people worldwide and three million people in the U.S.  Anyone can develop epilepsy; it occurs across all ages, races and genders.  Uncontrolled seizures and medication side effects pose challenges to independent living, learning and employment, so the goal of epilepsy treatment is seizure freedom with minimal side effects.  In the U.S., more than one million patients continue to have seizures despite initial therapy, and more than 800,000 continue to have seizures despite treatment with two or more therapies. (1),(2)

About Vimpat®
Vimpat® tablets and injection were launched in the US in May 2009 as an add-on therapy for the treatment of partial-onset seizures in people with epilepsy who are aged 17 years and older.  Vimpat® injection is a short-term replacement when oral administration is not feasible in these patients.  Vimpat® oral solution was launched in June 2010.  The availability of the oral tablets, oral solution, and intravenous (IV) injection allows for consistent treatment in a hospital setting.  The most common adverse reactions occurring in greater than or equal to 10 percent of Vimpat®-treated patients, and greater than placebo, were dizziness, headache, nausea, and diplopia.  Additional important safety information for Vimpat® is available at the end of the press release.

In the European Union, Vimpat® (film-coated tablets and solution for infusion) is approved as adjunctive therapy for the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 16 years and older. Vimpat® solution for infusion may be used when oral a
'/>"/>

SOURCE UCB, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Three-Year Clinical Outcomes from Use of Genous™ Stent in Large, Real-World Patient Population Demonstrate Long-Term Safety and Efficacy
2. Merz research Shows Long-term Benefits for Patients With Dystonia
3. AdCare Health Systems Selects Remedi SeniorCare for Long-Term Care Pharmacy Solutions
4. Clinical Data Demonstrates Long-Term Safety of Boston Scientifics Alair[TM]Bronchial Thermoplasty System
5. Novus Scientific Announces the Worlds 1st Long-Term Absorbable Mesh as an Alternative to Non-Absorbable Synthetic Mesh
6. Rescheduled Webcast: Isis Pharmaceuticals Hosts Dr. John Kastelein to Review Mipomersen Long-term Data Recently Presented at ESC Congress 2011
7. Webcast Alert: Isis Pharmaceuticals Hosts Dr. John Kastelein to Review Mipomersen Long-term Data Recently Presented at ESC Congress 2011
8. NIH-Funded Study Demonstrates That Patients Receiving New CPR Devices (ResQPOD® and ResQPump™) and Cooling Have Improved Long-Term Brain Function Following Cardiac Arrest
9. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
10. Novocure Announces Long-Term Supply Agreement With ITT Corporation for Ceramic Sensor Technology
11. Analysis Compares Cost-Effectiveness of Premixed Insulin Analogs to Long-Acting Insulin Analogs in the Long-Term Treatment of Type 2 Diabetes in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  HyGreen, Inc., a leader in hand hygiene monitoring, ... Medical, a subsidiary of Ascendis Health Limited, in ... year, hundreds of millions of patients around the world ... transmitted from patient to patient via the unwashed hands ...
(Date:1/23/2015)... 2015 Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC ...  filed a Preliminary Proxy Statement, Schedule 14A, with the U.S. ... an update for shareholders detailing why a "YES" vote to ... Dear Shareholders, As we reflect upon the 2014 ...
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 The Incredible ... Bodybuilder Ben Pakulski to increase lean muscle by up to ... has caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an ... that it is a step-by-step, scientific diet formula that allows ...
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
(Date:1/22/2015)... has released a new blog post explaining the main features ... , Auto insurance quotes help many drivers find the best ... call an agent or visit an agency for price information. ... http://autocarinsurancebest.com/ . , Every business who relies heavily on ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... Four years since the release of their debut recording ... marriage of Avasa & Matthew Love – the duo are pleased ... release through White Swan Records on February 24, 2015. , THE ... path available to all of us to walk out of the ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... plant research centre at University of Newcastle upon ... Research found that green and black tea inhibit ... on Alzheimer's Disease. Alzheimer's is a form of ... people worldwide., ,According to the journal, tea ...
... findings of a recent study researchers say that the circadian ... , can significantly impact lung function and help determine peak ... ,During the study changes in lung function between 8:00 a.m. ... study, which tracked 4,835 patients undergoing breathing tests at various ...
... one of the leading causes of disability and death in ... the best approach. Obesity in middle-aged men can have a ... life, according to a new study. ,7,402 healthy men ... 28 years. Fatal and non-fatal incidences of stroke were recorded ...
... New research shows that sleep disorders may be linked ... ADD ), // neuromuscular conditions, and psychiatric problems. ... patients with sleep apnea also had ADD. Results also ... insomnia. Further testing showed some of these patients also ...
... should probably be tested to see if they carry ... according to findings of a recent study. Helicobacter pylori ... been linked to stomach cancer. However researchers are baffled ... bypass surgery a weight loss operation in which food ...
... interferon are found to protect people with early stages of ... followed up on a previous study which showed that beta ... early evidence of MS and found people who have the ... medication had their brain tissue decline on average by 1.18 ...
Cached Medicine News:
... Model 6495 Bipolar Coaxial Temporary Pacing Lead ... bipolar technology based on the sensing and ... Unipolar Temporary Pacing Lead., ,The Streamline Temporary ... temporary sensing and pacing during and after ...
... of temporary sensing and pacing leads. Our ... temporary pacing leads and improved upon the ... and less traumatic to heart tissue. , ... to provide consistent temporary sensing and pacing ...
... device was designed specifically to obviate the ... The eNcloseII device can provide the surgeon ... better hemodynamics as compared to partial occlusion ... suggested that complete or partial clamping of ...
... Carpentier-Edwards Classic annuloplasty rings have ... choice for more than 30 ... restore the anatomical size and ... to help prevent recurrent dilatation. ...
Medicine Products: